This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2002 Remove Public Health Remove World Health Related Topics
FDA Licensing Compliance COVID-19 Governance Pharmaceutical Industry Hospitals More Related Topics >
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2024

SQA

FEBRUARY 26, 2024

These are requirements of the Therapeutic Goods (Medical Devices) Regulations 2002. The MDVP pilot aims to identify areas that may require improvement in order to ensure appropriate monitoring and communications are in place to support the ongoing safety of medical devices available to the Australian public.

FDA 52
FDA Compliance COVID-19 Public Health 52
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – September/October

SQA

DECEMBER 16, 2022

It will also facilitate cross-border circulation of these critical health therapies as well as cross-border cooperation between public health authorities. This proposal builds upon the existing legal framework, which came into force in 2002 for blood and 2004 for tissues and cells.

FDA 40
FDA Compliance COVID-19 Licensing 40
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 50,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024